Skip to main content

Table 6 Sensitivity of the MDASI-MM to impact of therapy: comparison of subscale and individual symptom scores pre-HSCT and 7 days post-HSCT ( n = 66)

From: Validation of the M. D. Anderson Symptom Inventory multiple myeloma module

 

Pre-HSCT

Post-HSCT

Differencea

Effect size

 

Mean

SD

Mean

SD

  

MDASI-MM subscales

      

 Core

1.60

1.30

3.57

1.76

1.97b

1.29

 Severity

1.43

1.14

3.21

1.62

1.78b

1.33

 Interference

2.32

2.29

4.51

2.62

2.19b

0.95

Individual items

      

 Lack of appetite

0.96

1.77

5.73

3.14

4.77b

1.43

 Diarrhea

0.56

1.25

5.37

3.39

4.81b

1.36

 Nausea

0.36

0.96

4.38

3.28

4.02b

1.20

 Dry mouth

1.22

2.14

4.94

3.35

3.72b

1.11

 Fatigue

2.99

2.52

5.86

2.40

2.87b

1.07

 Drowsiness

1.88

2.12

4.53

2.56

2.65b

0.88

 Mouth/throat sores

0.34

0.99

2.82

3.29

2.48b

0.81

 Vomiting

0.06

0.29

2.29

3.16

2.23b

0.70

 Muscle weakness

1.92

2.10

3.45

2.37

1.53b

0.56

 Disturbed sleep

2.47

2.61

4.03

2.79

1.56b

0.49

 Distress

1.82

2.41

3.03

2.91

1.21b

0.48

 Pain

2.84

2.80

4.11

2.98

1.27c

0.44

 Sadness

1.37

2.34

2.05

2.92

0.68c

0.30

 Difficulty paying attention

1.06

1.57

1.57

2.01

0.51c

0.29

 Shortness of breath

0.81

1.54

1.39

2.12

0.58c

0.25

 Rash

0.38

1.33

0.88

2.00

0.50

0.21

 Constipation

0.95

1.67

0.65

1.96

−0.30

0.20

 Difficulty remembering

1.21

1.90

1.44

1.83

0.23

0.15

 Numbness

2.90

3.00

2.70

2.99

−0.20

0.09

 Bone aches

2.31

2.38

2.48

2.76

0.17

0.03

  1. a Positive values indicate mean increase in symptoms post-HSCT; negative indicate mean symptom improvement.
  2. b Significant at P < .001.
  3. c Significant at P < .05.